ERBB2 and neoplasm: Dr Gianni said that the therapeutic role and wide applicability of dual HER2-blockade with monoclonal antibodies is established but newer therapeutic approaches to improve the overall results of CLEOPATRA to address the different biology and different drug sensitivity of subsets of HER2-positive tumours should be done.